<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1077">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02293915</url>
  </required_header>
  <id_info>
    <org_study_id>971-III</org_study_id>
    <nct_id>NCT02293915</nct_id>
  </id_info>
  <brief_title>An Efficacy and Safety Study of Sodium Oligo-mannurarate (GV-971) Capsule for the Treatment of Alzheimer's Disease</brief_title>
  <official_title>Phase III Study of Sodium Oligo-mannurarate (GV-971) Capsule on Mild to Moderate Alzheimer Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Greenvalley Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Greenvalley Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to determine the efficacy and safety of Sodium&#xD;
      Oligo-mannurarate (GV-971) in 36-week treatment of mild to moderate Alzheimer's disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2014</start_date>
  <completion_date type="Actual">September 28, 2018</completion_date>
  <primary_completion_date type="Actual">June 29, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement of Alzheimer's Disease Assessment Scale-cognitive subscale(ADAS-cog)/12 of sodium oligo-mannurarate capsule</measure>
    <time_frame>36 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement of Clinician's Interview-Based Impression of Change Plus(CIBIC-plus) of sodium oligo-mannurarate capsule</measure>
    <time_frame>36 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of Alzheimer's Disease Cooperative Study/Activities of Daily(ADCS-ADL) of sodium oligo-mannurarate capsule</measure>
    <time_frame>36 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of Neuropsychiatric Inventory(NPI) of sodium oligo-mannurarate capsule</measure>
    <time_frame>36 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose metabolism of bilateral temporoparietal cortex</measure>
    <time_frame>36 weeks</time_frame>
    <description>Obtained by Positron Emission Tomography in two sites.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">818</enrollment>
  <condition>Mild to Moderate Alzheimer Disease</condition>
  <condition>Cognitive Impairment</condition>
  <arm_group>
    <arm_group_label>sodium oligo-mannurarate 900mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium oligo-mannurarate 900mg</intervention_name>
    <description>sodium oligo-mannurarate capsule 900mg twice a day for 24 weeks</description>
    <arm_group_label>sodium oligo-mannurarate 900mg</arm_group_label>
    <other_name>GV-971</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>simulant of sodium oligo-mannurarate capsule</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Aged 50-85 years (inclusive), no gender limitation;&#xD;
&#xD;
          2. Female subjects should be postmenopausal women (menopause &gt;24 weeks), surgically&#xD;
             sterilized women or women of child bearing age who agree to take effective&#xD;
             contraceptive measures during the trial. Women of child bearing age and women less&#xD;
             than 24 weeks from menopause must undergo urine pregnancy test in screening period and&#xD;
             result must be negative;&#xD;
&#xD;
          3. Subjects have received education in primary school and above and are able to complete&#xD;
             protocol specified cognitive ability test and other tests;&#xD;
&#xD;
          4. Impaired memory for at least 12 months, with a tendency of progressive aggravation;&#xD;
&#xD;
          5. Meet diagnostic criteria of probable AD according to National Institute of&#xD;
             Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and&#xD;
             Related Disorders Association (NINCDS-ADRDA) (1984);&#xD;
&#xD;
          6. Patients with mild to moderate disease, i.e. 11 ≤total MMSE score ≤26 (for subjects&#xD;
             with primary school education, 11 ≤total MMSE score ≤22);&#xD;
&#xD;
          7. Total Hachinski Ischemia Scale (HIS) score ≤4 ;&#xD;
&#xD;
          8. Total Hamilton Depression Scale/17-item (HAMD) score ≤10;&#xD;
&#xD;
          9. In screening, cranial MRI plain scan and oblique coronal hippocampus scan must be&#xD;
             performed, lacunar infarction lesions with a diameter larger than 2 cm ≤2, without&#xD;
             lacunar infarction lesion in vital sites, such as thalamus, hippocampus, entorhinal&#xD;
             cortex, paraolfactory cortex, cortex and other subcortical gray matter nuclei; MRI&#xD;
             shows highest possibility of Alzheimer's disease (medial temporal lobe atrophy visual&#xD;
             rating scale MTA grade ≥2);&#xD;
&#xD;
         10. Neurological examination shows no significant sign;&#xD;
&#xD;
         11. Subjects should have stable, reliable caregivers, or at least have frequent contact&#xD;
             with caregivers (at least 4 days every week, at least 2 h every day), and caregivers&#xD;
             will help patients in participation in this study. Caregivers must accompany subjects&#xD;
             to participate in study visits and have sufficient interaction and communication with&#xD;
             subjects, so as to provide valuable information on NPI, ADCS-ADL, CIBIC-plus scales.&#xD;
&#xD;
         12. Before implementation of any protocol related procedure or examination, subjects must&#xD;
             sign the written informed consent form. If subjects can not sign due to limited&#xD;
             cognition, legal guardians should sign on behalf of subjects and meanwhile, legal&#xD;
             guardians should also sign the informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Participate in another clinical trial within 30 days prior to initiation of this&#xD;
             study;&#xD;
&#xD;
          2. Pregnant or nursing women;&#xD;
&#xD;
          3. Dementia due to other causes: vascular dementia, central nervous system infection&#xD;
             (e.g. AIDS, syphilis), Creutzfeldt-Jakob disease, Huntington's chorea, Parkinson's&#xD;
             disease, dementia with Lewy bodies, traumatic dementia, other physical and chemical&#xD;
             factors (e.g. drug poisoning, alcoholism, carbon monoxide poisoning), significant&#xD;
             physical illness (e.g. hepatic encephalopathy, pulmonary encephalopathy), intracranial&#xD;
             occupying lesion (e.g. subdural hematoma, brain tumor), endocrine disorders (e.g.&#xD;
             thyroid disease, parathyroid disease) and dementia caused by vitamin or other factors;&#xD;
&#xD;
          4. Previous nervous system disorders (including stroke, optic neuromyelitis, Parkinson's&#xD;
             disease, epilepsy);&#xD;
&#xD;
          5. Abnormal laboratory values: liver function (ALT, AST) &gt; 1.5 times of upper limit of&#xD;
             normal, Cr &gt; 1.5 times of upper limit of normal, white blood cell count, platelet,&#xD;
             hemoglobin below the lower limit of normal, blood glucose &gt;1.5 times of upper limit of&#xD;
             normal;&#xD;
&#xD;
          6. In screening, systolic blood pressure ≥160 mmHg or &lt;90 mmHg, or diastolic blood&#xD;
             pressure ≥100 mmHg or &lt;60 mmHg;&#xD;
&#xD;
          7. Unstable or severe cardiac, pulmonary, hepatic, renal or hematopoietic disease&#xD;
             (including unstable angina, uncontrolled asthma, active gastric bleeding and cancer),&#xD;
             after 10 min rest, resting heart rate &lt;55 bpm;&#xD;
&#xD;
          8. Visual or hearing disorder, preventing completion of neuropsychological test and scale&#xD;
             evaluation;&#xD;
&#xD;
          9. In screening, MRI examination shows significant focal lesions, more than 2 lacunar&#xD;
             infarction lesions with a diameter &gt;2 cm, lacunar infarction lesions in vital sites,&#xD;
             such as thalamus, hippocampus, entorhinal cortex, paraolfactory cortex, cortex and&#xD;
             other subcortical gray matter nuclei; Fazekas scale for white matter lesions at ≥&#xD;
             grade 3;&#xD;
&#xD;
         10. Alcohol abuse or drug abuse;&#xD;
&#xD;
         11. Patients with psychosis, including severe depression;&#xD;
&#xD;
         12. Patients who are using drugs for Alzheimer's disease which can not be stopped;&#xD;
&#xD;
         13. Use of heparin, Propylene Glycol Mannurate Sulfate or Alginric Sodium Diester within 3&#xD;
             weeks prior to screening;&#xD;
&#xD;
         14. Inability to take trial drugs according to prescription, previous non-compliance with&#xD;
             prescription or possibility of non-compliance with study treatment in the trial;&#xD;
&#xD;
         15. Investigators consider subjects can not complete this study;&#xD;
&#xD;
         16. Subjects in the phase II trial of the study drug;&#xD;
&#xD;
         17. Subjects are investigators participating in this study or their direct relatives,&#xD;
             staff of Quintiles (Shanghai) or Shanghai Greenvalley Pharmaceutical Co., Ltd. or&#xD;
             their direct relatives.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Beijing</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100005</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chongqing</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400010</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fujian</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guangzhou</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wuhan</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430077</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Changsha</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nanjing</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Suzhou</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yangzhou</name>
      <address>
        <city>Yangzhou</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jinan</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xi'an</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sichuan</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tianjin</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300052</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hangzhou</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310016</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wenzhou</name>
      <address>
        <city>Wenzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>November 13, 2014</study_first_submitted>
  <study_first_submitted_qc>November 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2014</study_first_posted>
  <last_update_submitted>October 9, 2018</last_update_submitted>
  <last_update_submitted_qc>October 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

